Cooperating oncogenes in cancer
AssigneeCold Spring Harbor Laboratory
InventorsLars Zender, Scott W. Lowe, Mona S. Spector, Wen Xue
Life of this patent
Estimating the term…
Abstract
This invention provides methods of diagnosis, drug screening, and treatment based on the discovery that cIAP1 and Yap are co-amplified oncogenes that cooperate to contribute to oncogenesis and tumor maintenance.
Claims31
A method of diagnosing liver cancer in a human patient, comprising:
- providing a DNA sample from the liver of the patient, and
- detecting, in said DNA sample, amplification of a nucleic acid sequence in chromosomal region 11q22, wherein said amplification indicates that the patient has, or is susceptible of developing, liver cancer.
The method of embodiment 1, wherein the nucleic acid sequence is from a cIAP1, cIAP2 or Yap gene.
A method of selecting a cancer patient for treatment with an inhibitor of CDK, RAF, or MEK, comprising:
- providing a DNA sample from the cancer tissue of the patient, and
- detecting, in said DNA sample, amplification of a nucleic acid sequence in chromosomal region 11q22, wherein said amplification indicates that the patient will be responsive to said treatment.
A method of selecting a liver cancer patient for treatment with an IAP inhibitor, comprising:
- providing a DNA sample from the liver cancer tissue of the patient, and
- detecting, in said DNA sample, amplification of a nucleic acid sequence in chromosomal region 11q22, wherein said amplification indicates that the patient will be responsive to said treatment.
A method of inhibiting the growth of a cancer cell, comprising contacting the cell with an interfering RNA that inhibits the expression of Yap.
A method of identifying a molecule for treating cancer, comprising:
- providing a sample comprising Yap,
- contacting said sample with a candidate molecule, and
- detecting, in said sample, a decrease in the activity of said Yap, wherein said decrease indicates that the candidate molecule is useful for treating cancer.
A mouse at least some of whose cells comprise a genome comprising a heterologous nucleic acid sequence comprising a Yap-coding sequence and an expression control sequence linked operatively thereto, wherein the mouse has cancer, or is more susceptible of developing cancer as compared to a control mouse not having said heterologous nucleic acid sequence.
A mammalian cell comprising (1) a first heterologous nucleic acid sequence comprising a Yap-coding sequence and a first expression control sequence linked operatively thereto, and (2) a second heterologous nucleic acid sequence comprising a cLAP1-coding sequence and a second expression control sequence linked operatively thereto.
A method of inhibiting the growth of a cancer cell, comprising contacting the cell with a first interfering RNA that inhibits the expression of Yap and an inhibitor that inhibits the activity of cIAP1.
A method of treating cancer, comprising administering to a cancer patient an inhibitor of cIAP1 or cIAP2 and an inhibitor of MEK or CDK.
A method of treating cancer, comprising administering to a cancer patient a shRNA against Yap and an inhibitor of MEK or CDK.
A method of treating cancer, comprising administering to a cancer patient an inhibitor of cIAP1 and a shRNA against Yap.
A method of treating cancer, comprising administering to a cancer patient (1) an inhibitor of cIAP1 or CIAP2, or a shRNA against Yap, and (2) a chemotherapy agent.
Dependencies are inferred from the claim text.